Centene Corp | CNC | Long at $35.00Centene Corp NYSE:CNC is a healthcare enterprise providing programs and services to under-insured and uninsured families, commercial organizations, and military families in the U.S. through Medicaid, Medicare, Commercial, and other segments. The stock dropped almost 40% this morning due to recent challenges, such as a $1.8B reduction in 2025 risk adjustment revenue and rising Medicaid costs (leading to withdrawal of 2025 earnings guidance). However, the company has a book value near $56, debt-to-equity of 0.7x (healthy), a current P/E of 5x, and a forward P/E of 9x.
It may be a few years before this stock recovers. But the price has entered my "crash" simple moving average area (currently between $32 and $36) and there is a price gap on the daily chart between $32 and $33 that will likely be closed before a move higher. Long-term, and potentially a new political administration, new life may enter this stock once again as the baby boom generation requires more healthcare services. But holding is not for the faint of heart...
Thus, at $35.00, NYSE:CNC is in a personal buy zone with a likely continued dip into the low $30s or high $20s before a slow move higher (where I will be accumulating more shares). Full disclosure: I am also a position holder in the $60s and cost averaging down.
Targets into 2028:
$45.00 (+28.6%)
$54.00 (+54.3%)
Healthcarestocks
Oscar (OSCR) – Tech-Enabled Healthcare with Margin Momentum Company Snapshot:
Oscar NYSE:OSCR Health is a technology-focused health insurer leveraging data and digital platforms to deliver affordable, personalized care. Its platform-centric model improves member experience, cost control, and care outcomes—setting it apart in a highly regulated sector.
Key Catalysts:
Steady Execution Under Proven Leadership 🧠
CEO Mark Bertolini (ex-Aetna) brings credibility and strategic clarity, reinforcing investor trust in Oscar’s long-term viability.
Focus remains on operational discipline, risk management, and scalable infrastructure.
2025 Guidance Reaffirmed 📊
Following a solid quarter, Oscar reaffirmed full-year 2025 guidance, projecting margin expansion and sustained growth despite sector headwinds.
Medical loss ratio (MLR) held steady at 75.4%, absorbing a $31M prior-period hit—showing resilience in cost containment.
Robust Financial Flexibility 💰
With $1B+ in free cash flow, Oscar is well-positioned for:
Organic growth in new markets
Potential share buybacks or dividends
Continued investment in digital infrastructure
Investment Outlook:
Bullish Entry Zone: Above $17.00–$17.50
Upside Target: $32.00–$33.00, supported by margin stability, capital strength, and smart execution.
🩺 Oscar is transforming health insurance from reactive to predictive—backed by tech, discipline, and capital strength.
#OscarHealth #OSCR #HealthTech #InsurTech #DigitalHealth #MarkBertolini #MedicalLossRatio #FreeCashFlow #TechEnabledCare #HealthcareStocks #Bullish #ValueDelivery #HealthInnovation
KALH Upside Potential?Looking purely off of KALV with the range that it has been in and the healthcare sector that it is a part of. IF healthcare sector will continue to rebound, this stock could potentially rebound as well back to the $13-$15 range. It is currently sitting right below the 200 day moving average and seems to be holding support there. I'm considering a stop loss just below $11 since this stock can move $0.83 a day with a trailing stop loss of 9%. I see it is valued under pressure of the VWAP that is currently at $12.20. This could be a beautiful continuation of the long trend that it has been in since January 2025 with an entry on this pullback. RSI looks like it is exhausting out with oversold conditions at 37.30. I like the inverted hammer that was placed and the fact that we have 3 days worth of support on the 200 day moving average.
On the fundamentals, this company is a cash king in the fact they have more cash than debt. Market Cap 567.26M vs. Enterprise Value 420.76M and Insider ownership is key: Insider Ownership: 22.58%. All of which show that management are in charge and have a vision.
As always, do your own research and due diligence. Not trading advice.
eHealth | EHTH | Long at $4.22eHealth NASDAQ:EHTH , the largest online private health insurance marketplace, may be undervalued. The book value is listed around $19 a share and it has a debt-to-equity of 0.07x (healthy), a quick ratio of 2.5 (strong liquidity, can cover liabilities), growing revenue since 2021 (over $500M in 2024), and insiders have recently bought shares/awarded options. However, profitability is still a concern, but the company is expected to be profitable by 2026. With the US's aging population and the need for affordable healthcare coverage, eHealth *may* standout as a major insurance marketplace... but time will tell.
From a technical analysis perspective, the stock price is near the bottom of its historical simple moving average. I do not doubt, however, that the stock may slip to cover the small price gap between $3.09 and $3.23 (which will be another entry point if fundamentals do not change). This stock may trade sideways for some time. But it has a 27M float and as we saw in 2014 and 2020, it can REALLY get going if buyers see the opportunity...
Thus, at $4.22, NASDAQ:EHTH is in a personal buy zone with more opportunity potentially near $3 in the future.
Targets:
$6.00 (+42.2%)
$8.00 (+89.6%)
Regeneron Pharmaceuticals | REGN | Long at $502.28Regeneron Pharmaceuticals NASDAQ:REGN stock dropped more than 17% today due to mixed Phase 3 trial results for itepekimab, a potential COPD drug. However, the company has an extensive drug pipeline, raked in over $14 billion last year, and is currently trading at a price-to-earnings of 15x. Debt-to-equity is 0.09x (extremely healthy) and earnings are forecast to grow 7.5% per year. While 2025 is anticipated to be its "worst" earnings year, the outlook through 2028 looks like steady growth in revenue and cash flow.
From a technical analysis view, the stocks entered my "crash" simple moving average zone today (currently between $466 and $502). More often than not, this area signals a bottom in the near-term, but it's not guaranteed. I wouldn't be surprised if the $450s-$460s get hit before a reversal if the market shifts negatively - which will be another entry for me. If it moves into my "major" crash zone in the $300s to close more gaps on the daily chart, I will be piling into this stock heavily (like I did with NYSE:UNH ) for a longer-term hold - of course, unless fundamentals change. I'm going to keep my target small unless there is a "major crash" and eye the closing of the nearest price gap on the daily. There is another between $883-$914...
Targets:
$590 (+17.5%)
UnitedHealth Group | UNH | Long at $323.00UnitedHealth Group NYSE:UNH currently has a P/E near 15x, steady rising revenue (2024 = $400+ billion), EPS of 6.24x, dividend of 2.2%, and earnings are forecast to grow by 10.8% per year. The stock, however, has plummeted recently due to negative news, rising healthcare costs, CEO changes, and suspension of 2025 outlook. Every company has bumps, but I view solid companies like NYSE:UNH as pure opportunities for long-term investment - especially with America's aging population.
From a technical analysis perspective, the stock price has entered my "crash" simple moving average zone (which currently extends down near $307.00). Personally, this is the zone I am starting a position due to the odds of a future bounce from here. However, I am very aware that there is an open price gap near $265.00 that may get filled this year or early next. I could see a bounce in my crash zone to bring in the bulls and then a drop to that level to heighten the fear. That is another area I plan to grab more shares and build a strong position. But, in case it doesn't extend that low, I have started a position at $223.00, with future investments near $307.00 and below. I doubt this will be a quick turnaround stock - patience is where money is made.
Targets (into 2028):
$375.00
$475.00
$580.00
GE Healthcare Technology | GEHC | Long at $62.25GE Healthcare Technology $NASDAQ:GEHC. An aging and unhealthy population will only create an increased need for healthcare imaging services. Add AI to the diagnostic mix, and imaging will be imperative for routine health maintenance and screening. With a P/E of 15x, debt-to equity of 1x, earnings forecast growth of 8.36% per year, and bullish analyst ratings, this could be a good value play for the patient.
Thus, at $62.25, NASDAQ:GEHC is in a personal buy zone. Further drops are possible if trade wars make imaging materials/technology difficult to obtain, but that general statement applies to the whole market at this time...
Targets:
$70.00
$78.00
Acadia Healthcare Company | ACHC | Long at $21.98Acadia Healthcare's NASDAQ:ACHC stock has fallen nearly -76% in a year, primarily due to weak 2024 results, missed revenue and EPS expectations, and a soft 2025 revenue guidance. Ongoing federal investigations into billing practices and lawsuits have further eroded investor confidence. However, it is currently trading at a price-to-earnings ratio of 7.42x and earnings are forecast to grow 7.07% per year. The profitable company is trading at a good value compared to other healthcare companies. Debt-to-equity is relatively low (0.64x), but legal risks (DOJ probe, lawsuits) strain margins.
The stock has entered my "major crash" simple moving average territory and there is a lot of downward / selling pressure. But, more often than not, this area (which... I caution... still extends down near $16) can often signal a temporary or longer-term bottom. Personally, this is a buy area ($16-$21) even if it turns into a short-term bounce in 2025. But I believe the overall market moves in the S&P 500, etc. will guide this stock more than anything at this point (unless more bad news about the company emerges).
One thing to note is that there are open price gaps on the daily chart near $17, $10, and $8. These gaps, which often (but not always) get closed in the lifetime of a stock, are a potential signal for further declines - at least at some point. There could be a drop near $16, then a $10-$20 bullish price increase after that, followed by more declines (trapping investors). Time will tell, but NASDAQ:ACHC is currently attractively valued. From a technical analysis standpoint, it is in a personal "buy zone", even if purely for a swing trade.
Targets:
$27.00
$33.00
$39.00
HCA Healthcare | HCA | Long at $299.00NYSE:HCA Healthcare: P/E of 13x, earnings are forecast to grow 6.01% per year; earnings have grown 10.6% per year over the past 5 years, and trading at good value compared to peers and industry.
From a technical analysis perspective, it dipped to my selected historical simple moving average area and may represent a buying opportunity to fill the daily price gap up to $394.00. Thus, NYSE:HCA is in a personal buy zone at $299.00.
Target #1 = $324.00
Target #2 = $362.00
Target #3 = $394.00
$UNH: UnitedHealth Group – Healthcare Hero or Reform Risk?(1/9)
Good evening, everyone! 🌙 NYSE:UNH : UnitedHealth Group – Healthcare Hero or Reform Risk?
With UNH at $505.69, post-7% drop, is this healthcare giant a safe bet or a reform casualty? Let’s diagnose! 🔍
(2/9) – PRICE PERFORMANCE 📊
• Current Price: $ 505.69 as of Mar 18, 2025 💰
• Recent Move: Stable after 7% drop, per user data 📏
• Sector Trend: Healthcare sector mixed with reforms and economic factors 🌟
It’s a steady pulse—let’s see if it’s time to buy or hold! ⚙️
(3/9) – MARKET POSITION 📈
• Market Cap: Approx $465B (920M shares) 🏆
• Operations: Health insurance and services across the U.S. ⏰
• Trend: Leading player with strong fundamentals, per data 🎯
Firm in healthcare, but reforms keep it on its toes! 🏥
(4/9) – KEY DEVELOPMENTS 🔑
• Mixed News: Healthcare reforms debated, earnings reports mixed, per user data 🌍
• Q4 2024 Earnings: Assume beat or miss based on context, per data 📋
• Market Reaction: Stabilized after drop, showing resilience 💡
Navigating through choppy waters! 🛳️
(5/9) – RISKS IN FOCUS ⚡
• Healthcare Reforms: Regulatory changes could impact business 🔍
• Competition: Other insurers and providers in the market 📉
• Economic Slowdown: Reduced consumer spending on healthcare ❄️
It’s a risky prescription—watch the side effects! 🛑
(6/9) – SWOT: STRENGTHS 💪
• Market Leader: Dominant in U.S. healthcare 🥇
• Diversified Portfolio: Insurance and services balance risk 📊
• Financial Strength: Strong earnings and cash flow, per data 🔧
Got the muscle to handle challenges! 🏦
(7/9) – SWOT: WEAKNESSES & OPPORTUNITIES ⚖️
• Weaknesses: Regulatory scrutiny, high debt (if any) 📉
• Opportunities: Aging population, tech advancements in healthcare, per data 📈
Can it capitalize on growth or stumble on weaknesses? 🤔
(8/9) – POLL TIME! 📢
UNH at $505.69—your take? 🗳️
• Bullish: $600+ soon, reforms are manageable 🐂
• Neutral: Steady, risks balance out ⚖️
• Bearish: $450 looms, reforms hit hard 🐻
Chime in below! 👇
(9/9) – FINAL TAKEAWAY 🎯
UNH’s $505.69 price reflects stability after a drop, with mixed news and reforms in play 📈. DCA-on-dips could be a strategy to manage volatility. Gem or bust?
Zoetis | ZTS | Long at $156.94Zoetis NYSE:ZTS , the largest global animal health company, generated more than $9 billion in revenue in 2024 and earnings have grown 9.3% per year over the past 5 years. Free cash flow for FY2024 was over $2.2 billion. Dividend consistently raised every year for the past for years (currently 1.28%). The growth of the company isn't expected to slow any time soon, and I believe the animal health care market will grow right alongside the human health care market - if not potentially faster (people love their pets).
Thus, at $156.94, NYSE:ZTS is in a personal buy zone. There may be some near-term risk with the potential for a daily price-gap close near $136.00, but I personally view that as an even better buy opportunity (unless fundamentals change).
Targets
$170.00
$180.00
$200.00
Potential outside week and bullish potential for OPTEntry conditions:
(i) higher share price for ASX:OPT above the level of the potential outside week noted on 17th January (i.e.: above the level of $0.85).
Stop loss for the trade would be:
(i) below the low of the outside week on 13th/16th January (i.e.: below $0.725), should the trade activate.
$TLSA Poised For An 85% Surge Amidst Alzheimer’s Drug BoomTiziana Life Sciences Ltd (NASDAQ: NASDAQ:TLSA ), a stock that has been under the radar, is now showing strong signals of a potential breakout. With a falling wedge pattern and a bullish RSI reading, coupled with the growing interest in Alzheimer’s drug development, NASDAQ:TLSA is positioning itself as a stock to watch in 2025.
Technical Analysis
As of the time of writing, (NASDAQ: NASDAQ:TLSA ) shares are down 5.52%, but this dip is likely a temporary setback. The stock’s Relative Strength Index (RSI) stands at 52.77, which, despite the recent decline, suggests that bullish momentum is building. The RSI is neither overbought nor oversold, indicating a healthy consolidation phase before a potential upward move.
The most Intriguing technical indicator is the falling wedge pattern that has formed since January 23. This pattern is typically a bullish reversal signal, especially after a prolonged downtrend. The falling wedge is characterized by converging trendlines that slope downward, with the price making lower highs and lower lows. As the pattern nears its apex, the likelihood of a breakout increases.
For NASDAQ:TLSA , the immediate support lies at the 78.6% Fibonacci retracement level. A pullback to this zone could serve as an excellent buying opportunity for traders, as it aligns with recent resistance-turned-support levels. On the upside, the 38.2% Fibonacci retracement level is acting as a pivot point. A breakout above this level could ignite a bullish rally, potentially propelling the stock toward an 85% surge.
Alzheimer’s Drugs – The Next Big Market Opportunity
While the technical setup is compelling, the story behind NASDAQ:TLSA is equally intriguing. The Alzheimer’s drug market is emerging as the next big opportunity, drawing parallels to the obesity drug boom led by companies like Eli Lilly and Novo Nordisk. With an estimated market value of $13 billion by 2030, according to Bloomberg Intelligence, the race to develop effective Alzheimer’s treatments is heating up.
Companies like Biogen Inc., Eli Lilly & Co., Novo Nordisk, and Roche AG are investing billions into Alzheimer’s research. Recent developments have shown promise, with two new drugs—Leqembi (developed by Biogen and Eisai) and Kisunla (by Eli Lilly)—already approved in the U.S. These drugs target amyloid plaques in the brain, slowing the progression of the disease in its early stages. However, they are not without challenges, as side effects like brain bleeding and swelling have been reported.
For (NASDAQ: NASDAQ:TLSA ) stock, this presents a unique opportunity. If the company is involved in Alzheimer’s research or has partnerships with major pharmaceutical players, it could benefit significantly from the growing interest in this sector. Even if NASDAQ:TLSA is not directly involved, the overall bullish sentiment in the healthcare and biotech sectors could provide a tailwind for the stock.
Additionally, any positive developments in Alzheimer’s drug trials or approvals could act as a catalyst for NASDAQ:TLSA , driving the stock higher. As Gregoire Biollaz, senior investment manager at Pictet Asset Management, noted, “It could be a year where we also see a bit more clarity in terms of traction for the drugs that are approved so far.”
Conclusion
NASDAQ: NASDAQ:TLSA is at a critical juncture, with both technical and fundamental indicators pointing to a potential surge. The falling wedge pattern suggest that the stock is building momentum, while the growing interest in Alzheimer’s drugs provides a strong fundamental catalyst. For investors seeking the next big opportunity, NASDAQ:TLSA could be the stock to watch in 2025.
As always, investors should conduct their own due diligence and consider their risk tolerance before making any investment decisions. However, with an 85% surge on the horizon, NASDAQ:TLSA is undoubtedly a stock worth keeping on your radar.
Figs Inc | FIGS | Long at $5.24Figs Inc $NYSE:FIGS. Technical analysis play first, fundamentals second.
My selected historical simple moving average lines have converged with the stock price, which often leads to sideways trading and a reversal in the downward trend (i.e. future price increase). The downward trend is flattening, but that doesn't mean post-earnings drop to $1.50-$2.00 isn't out of the question...
The FIGS brand is growing within the healthcare world with significant opportunities overseas. While economic headwinds may impede near/medium-term growth, revenue is anticipated to grow into 2027. EPS is expected to rise from 0.01 in 2024 to 0.20 by 2027. While this is not a "value" play and there is high risk for rug pulls, something may be brewing within the chart for a move up. Tread lightly, however...
Targets
$6.00
$6.40
$7.00
$8.00
Teladoc Health | TDOC | Long at $9.91Teladoc Health NYSE:TDOC - Initial position started at $9.91 with the potential for the price gap in the $7's to be closed in the near future (likely another entry there unless fundamentals change)
Pros:
User base of over 90 million and growing
Revenue grew from $555 million in 2019 to $2.6 billion through Q3 of 2024
Positive free cash flow since 2021
Low debt (debt to equity ratio around 1x)
AI integration and partnership with Amazon and Brightline
Historical simply moving average is approaching price, which often leads to a jump or change in downward momentum in the longer-term
Cons:
Currently unprofitable and not forecast to become profitable over the next 3 years
Lots of insider selling and exercising of options
No dividend
Daily price gap in the $7 dollar range which may close prior to move up
Targets through 2027 :
$14.20
$20.00
$27.00
$35.00
$55.00 (long-term, positive outlook)
Agilon Health | AGL | Long at $2.24Agilon Health NYSE:AGL
Pros:
Revenue consistently grew from 2019 ($794 million) to 2023 ($4.3 billion) and through three quarters of 2024 ($5.6 billion). Expected to reach $8.7 billion by 2027.
Current debt-to-equity ratio 0.06 (very low)
Sufficient cash reserves to fund operations and strategic initiatives
Strong membership growth (525,000 as of Q3 2024, a 37% year-over-year increase)
Recent insider buying ($2 - $3) and awarding of options
Cons:
Rising medical costs - currently unprofitable and not forecast to become profitable over the next 3 years
No dividend
Targets (into 2027):
$2.72
$4.00
$5.00
$7.00
$11.50
$16.00
Can a Pharmaceutical Giant Rewrite Its Own Destiny?In the complex world of global pharmaceuticals, Teva Pharmaceutical Industries Ltd. emerges as a compelling narrative of strategic reinvention. Under the leadership of CEO Richard Francis, the company has transformed from a struggling enterprise to a potential market leader, executing a bold "Pivot to Growth" strategy that has captured the attention of investors and industry experts alike. The company's remarkable journey reflects corporate resilience and a profound understanding of how strategic focus and innovative thinking can resurrect a seemingly faltering business.
Teva's renaissance is characterized by calculated moves that challenge traditional pharmaceutical business models. By strategically divesting its Japanese joint venture, selectively targeting high-potential generic markets, and developing promising drug candidates like Anti-TL1A, the company has demonstrated an extraordinary ability to reimagine its core strengths. The financial metrics tell a compelling story: a 66% market capitalization increase, double-digit revenue growth, and a strategic pipeline that promises future innovation in critical therapeutic areas such as neurology and digestive system treatments.
Beyond financial metrics, Teva represents a broader narrative of corporate transformation that extends beyond balance sheets. Its commitment to patient access programs, such as the recent inhaler donation initiative with Direct Relief, reveals a deeper organizational philosophy that intertwines strategic growth with social responsibility. This approach challenges the traditional perception of pharmaceutical companies as purely profit-driven entities, positioning Teva as a forward-thinking organization that understands its broader role in global healthcare ecosystems.
The company's journey poses a provocative question to business leaders and investors: Can strategic vision, relentless innovation, and a commitment to patient care truly redefine a corporation's trajectory? Teva's emerging story suggests that the answer is a resounding yes—a testament to the power of adaptive strategy, visionary leadership, and an unwavering commitment to pushing the boundaries of what's possible in the pharmaceutical landscape.
NDRA is a smaller portion of my long term bagNDRA with it's consistent dilution has been a little rough.
Had a small position go 88% down and that was my cue to toss more in to fix the average price.
I do believe the clinical trials pass with great results and this will be used complementary to MRI and other tech/procedures that are currently done and more that will be created into the future.
NOT FINANCIAL ADVICE
In the Genes for GH’s Path.Guardant Health is building strong bullish momentum, with a gap forming around the $21.50 level. A breakout above the $26.37 resistance would signal further upward movement, targeting the $37.05 weekly resistance. With an appealing 3.6 risk-to-reward ratio, this trade offers an attractive short-term opportunity, while a stop-loss at $19.19 ensures effective risk management.
In the longer term, Guardant Health’s bullish outlook could extend to $41.06, supported by its advancements in precision oncology and liquid biopsy technology. With growing adoption of early cancer detection and genomic testing, Guardant Health is positioned to capture increased market share as demand for cutting-edge diagnostics rises. For those with a longer-term view, holding with a $19.19 stop-loss provides an opportunity to capture potential upside while managing downside risk.
This combination of technical momentum and Guardant Health’s strong positioning in the healthcare innovation space supports a bullish push toward $37.05, with a longer-term target of $41.06.
Is Pfizer's Golden Goose About to Lay a Different Egg?Pfizer, the pharmaceutical giant that became a household name
during the pandemic, now faces a pivotal moment.
Activist investor Starboard Value has taken a $1 billion
stake, signaling potential changes on the horizon. But
what does this mean for Pfizer's future?
The company that swiftly developed a COVID-19 vaccine
now grapples with declining sales and a tumbling
stock price. Starboard's involvement brings both challenge and
opportunity. Will this be the catalyst for Pfizer's
renaissance or a sign of deeper troubles ahead?
Former Pfizer executives have been approached to assist
in the turnaround effort. Their potential involvement adds
an intriguing layer to this unfolding story. Could
their experience and insight be the key to
unlocking Pfizer's next chapter of success and innovation?
As the pharmaceutical landscape evolves post-pandemic, Pfizer's
response to this pressure could set industry trends.
Cost-cutting, strategic refocusing and potential leadership changes loom
large. How will these moves impact drug development,
patient care, and the broader healthcare ecosystem?
For investors, patients, and industry watchers, Pfizer's
next moves are crucial. Will the company
emerge stronger, leaner, and more innovative? Or will
it struggle to find its footing in a
rapidly changing market? The answers to these questions
could reshape the future of global healthcare.
MAXHEALTH - It is time for 1000?As always, the chart is easy to read and understand.
Here are a couple of highlights for this case study:
Observed a strong breakout with a long candle, currently in a retest phase.
Recent price action shows a clear buyer bias.
Key support levels are holding at 892 and 864.
The 21-weekly EMA provides additional support.
Volume spiked significantly in the last two weeks.
The healthcare sector is trending upward.
The first major resistance level to watch is around the 1000 mark.
Disclaimer: This analysis is for educational purposes only and should not be considered as financial advice or a recommendation to buy, sell, or hold any securities. The information provided is based on historical data and market observations and does not guarantee future performance. Please conduct your own research or consult with a financial advisor before making any investment decisions. Trading in the stock market involves risk, and past performance is not indicative of future results.